FOLFIRI方案治疗晚期胃癌的疗效观察

Clinical Study of FOLFIRI Regimen for Advanced Gastric Cancer

目的:观察FOLFIRI方案治疗晚期胃癌的近期疗效和毒副反应。方法:26例晚期胃癌患者,予FOLFIRI方案:伊立替康(CPT-11)180mg/m^2,静脉滴注1小时,第1天;亚叶酸钙(CF)200mg/m^2,静脉滴注2小时后5-氟脲嘧啶(5-Fu)400mg//m^2静脉推注,第1、2天,再予5-Fu 600mg/m^2持续滴注22小时,第1、2天。2周重复。化疗4个周期。结果:全组26例均可评价疗效,其中完全缓解(CR)1例,部分缓解(PR)10例,无变化9例,进展(PD)6例,总有效率(CR+PR)42.3%。毒副反应主要是骨髓抑制,发生率为84.6%(22/26),其次为胃肠道反应,恶心呕吐发生率为76.9%(20/26),腹泻38.5%(10/26),皮肤粘膜反应为30.8%(8/26)。结论:FOLFIRI方案治疗晚期胃癌的近期疗效好,毒副反应可耐受,可以推广。

Objective： To evaluate the therapeutic effects and adverse effects of irinotecan combined with 5-fluorouracil （5- Fu） and calcium folinate in the treatment for patients with advanced gastric cancer. Methods： Twenty-six patients with advanced gastric cancer received FOLF1RI chemotherapy regimen ： irinotecan（ CI：T- 11 ） 180mg/m2 intravenously, 1 hour, first day ; calcium folinate （CF）20Omg/m2 intravenously, two hours, the first and second day, 5＇-fluorouracil（5-Fu）400mg/m2 intravenous injection, the first and second day, followed by continuous infusion of 5-Fu 600mg/m2 for 22 hours, the first and second day. The efficacy was evaluated after 4 cycles. Results： One patient got complete response （CR） , 10 patients partial response （PR）, 9 patients no change（NC） and 6 patients progression disease（PD）. The total effective rate was 42. 3%. The major adverse reaction was myelosuppression （84.6%）, followed by gastrointestinal reaction including nausea, vomiting and diarrhea which had the incidence rates of 76.9% and 38. 5% respectively, and the skin and mucous membrane reaction was 30. 8%. Conclusion： This study shows that the regimen of FOLFIRI is effective and tolerable for advanced gastric cancer.